BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) saw its stock surge 9.72% during the after-hours trading session on Wednesday, February 19, 2025. The company's impressive fourth-quarter 2024 earnings and revenue, coupled with an optimistic outlook for 2025, fueled the rally.
In the fourth quarter, BioMarin reported better-than-expected adjusted earnings of $0.92 per diluted share, surpassing analysts' consensus estimate of $0.73. The company's revenue for the quarter stood at $747.3 million, outperforming the consensus estimate of $713.2 million.
The robust performance was driven by strong sales across BioMarin's key products. VOXZOGO, a treatment for achondroplasia, saw a remarkable 42% year-over-year increase in revenue to $208 million. The company's Enzyme Therapies portfolio, which includes treatments for rare genetic disorders, also contributed significantly, with sales rising 9% year-over-year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.